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Abstract Interactions with the bone marrow stroma regulate
dormancy and survival of breast cancer micrometastases. In
an in vitro model of dormancy in the bone marrow, we
previously demonstrated that estrogen-dependent breast
cancer cells are partially re-differentiated by FGF-2, re-
express integrin α5β1 lost with malignant transformation
and acquire an activated PI3K/Akt pathway. Ligation of
integrin α5β1 by fibronectin and activation of the PI3K
pathway both contribute to survival of these dormant cells.
Here, we investigated mechanisms responsible for the
dormant phenotype. Experiments demonstrate that integrin
α5β1c o n t r o l sde novo cytoskeletal rearrangements, cell
spreading, focal adhesion kinase rearrangement to the cell
perimeter and recruitment of a RhoA GAP known as GRAF.
This results in the inactivation of RhoA, an effect which is
necessary for the stabilization of cortical actin. Experiments
also demonstrate that activation of the PI3K pathway by
FGF-2 is independent of integrin α5β1 and is also required
for cortical actin reorganization, GRAF membrane relocali-
zation and RhoA inactivation. These data suggest that
GRAF-mediated RhoA inactivation and consequent pheno-
typic changes of dormancy depend on dual signaling by
FGF-2-initiated PI3K activation and through ligation of
integrin α5β1b yf i b r o n e c t i n .
Keywords Breastcancer.Dormancy.Fibronectin.GRAF.
Integrinα5β1.Micrometastases.PI3kinase.RhoGTPases
Introduction
Breast cancer cells form micrometastases to the bone
marrow in about a third of patients with localized disease
[1]. These cells become dormant in the bone marrow
microenvironment and survive chemotherapy administered
with the specific intent of eliminating them [2]. Very little is
known about mechanisms that keep these cells in a dormant
state. Direct data from individual breast cancer cells,
outnumbered more than 10
8-fold by hematopoietic progen-
itors, is not available. One of the limited options in
obtaining molecular data defining the behavior of these
cells is by development of models, initially with a limited
number of key components that define the in vivo system.
Such models can be expanded subsequently to include
additional key components in order to determine their
effects on the model and validate the data obtained.
Towards understanding basic elements of dormancy, we
developed an in vitro model incorporating three key elements
affecting breast cancer cell dormancy in the bone marrow
microenvironment [3]. The components of our system
consist of estrogen-dependent human breast cancer cell lines
MCF-7 and T-47D, fibronectin and basic fibroblast growth
factor (FGF-2) 10 ng/ml. Estrogen-dependent breast cancer
cell lines model estrogen-dependent human tumors, which
are likely to remain dormant for extended periods and are
least likely to have distant metastatic recurrences [4–6]. In
the clinical setting, recurrent estrogen receptor positive cells
continue to be estrogen sensitive and susceptible to hormonal
blockade [7, 8].
The second element of our system is fibronectin, a
structural protein of the bone marrow microenvironment in
physical contact with the dormant cells. Fibronectin is
found throughout the bone marrow and particularly in the
endosteum where homing hematopoietic stem cells have a
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with a characteristic cellular matrix formation in an
extensive network [10] by two types of bone marrow
stromal cells, the subendosteal reticulocytes and osteoblasts
[11]. Both have functional roles in hematopoiesis, with the
latter inducing low proliferation and high maintenance of
early haemopoietic progenitors, while reticulocytes promote
proliferation and differentiation in an in vitro co-culture
model [11]. Evidence suggests that metastatic breast cancer
cells usurp the hematopoietic niche and respond to signals
from the stromal elements [12]. Fibronectin is upregulated
in this pre-metastatic niche primed to receive metastatic
cancer cells [12]. In an in vitro co-culture system, tumor
cells binding to bone marrow stromal cells exclusively
depended on the fibronectin receptor integrin α5β1[ 10].
The third element of our model is basic fibroblast growth
factor (FGF-2). FGF-2 is a morphogenic differentiation
factor in mammary epithelial cells [13]. It inhibits the
proliferation of estrogen-dependent breast cancer cells [14]
and promotes their partial re-differentiation [15]. This
includes a diminished malignant potential in vitro, includ-
ing decreased motility and invasion [15, 16] and anchorage
independent growth [17] and decreased tumor growth in
murine xenografts [16]. Breast cancer cells transfected with
FGF-2 also form branching duct-like stuctures in Matrigel
[15]. FGF-2 is synthesized and exported by the stromal
cells [18, 19] and deposited in high concentrations in the
bone marrow microenvironment [18, 20–22].
In our model, breast cancer cells are incubated on
fibronectin-coated tissue culture plates in the presence of
FGF-2 10 ng/ml at clonogenic density, where their primary
interaction is with the substratum and not with each other
[3]. In the model, cells form dormant clones of 2–12 cells
over a 6-day period in contrast to cells incubated without
FGF-2, which form proliferating clones of greater than 30
cells. The dormant cells become growth arrested, re-express
integrins α2, α5, β1 β3a n dβ4, lost with transformation
[23–25], and adopt a characteristic morphogenic trait of
large size and a highly spread out conformation with large
cytoplasm to nucleus ratios [3]. They undergo sustained
activation of the phosphoinositol 3-kinase (PI3K) pathway
[3] and extracellular receptor kinase (ERK) pathway [26],
which, along with ligation of integrin α5β1, contribute to
their survival [3].
We wanted to determine the steady-state molecular
events that sustained dormancy in these cells. Specifically,
we wanted to discern whether the signaling mediating these
effects was initiated by FGF-2 directly or through integrin
α5β1, which is induced by FGF-2 incubation as the cells
reach a dormant steady-state. The phenotypic appearance of
the estrogen-dependent cells in the dormancy model was
reminiscent of that of FGF-2-transfected MDA-MB-231
cells. MDA-MB-231 cancer cells enforced to express FGF-
2 acquired a spread appearance, cortical redistribution of
fibrillar actin (F-actin), omnidirectional focal complex
activation [27], and decreased motility, invasiveness and
in vivo tumorigenicity [16]. We investigated the character-
istics of the dormant cells in the context of our prior
observations to determine if the partial re-differentiation of
the dormant cells was due to potential inhibitory effects on
the activation state of small GTPases, specifically RhoA,
implicated in actin polymerization and cancer progression
[28]. Our observations suggest that inhibition of RhoA,
which trends to higher expression with tumor grade and
nodal metastasis in breast cancer [29] ,m a yp l a ya
functional role in the partial re-differentiation of breast
cancer dormancy in the bone marrow microenvironment.
Materials and Methods
Cells and Cell Culture
MCF-7 cell were obtained from ATCC (American Type
Culture Collection) and cultured in Dulbecco’s modified
Eagle medium supplemented with 10% fetal calf serum
(DMEM/10% FCS) (standard medium) as before [3]. MCF-
10A cells (ATCC) were cultured in MCF-10 medium in
standard tissue culture plates, as before [30]. Cells were
incubated at clonogenic densities of 50,000–75,000 cells
per 10 cm fibronectin pre-coated plates purchased from
BIOCOAT, BD Biosciences, or 15,000 cells per well in 6
well plates (day -1) and supplemented with 10 ng/ml basic
FGF (FGF-2) (Invitrogen) the following day (day 0).
DMEM/10% FCS with FGF-2 10 ng/ml was replenished
on day 3, along with addition of inhibitors and antibodies in
specific experiments (LY 294002 25 μM (Calbiochem),
integrin α5β1o rα2β1 blocking antibodies 2 μg/ml
(Chemicon), integrin blocking peptides to fibronectin
(GRGDSP (P1)), to collagen (CQDSETRTFY (P3), and a
non-binding control (GRGESP (P2)) (American Peptide
Co., Sunnyvale, CA) 100 nM in 10% DMEM), as
previously described [3]. For all experiments except trans-
fections, cells were harvested and analyzed on day 6.
Indirect Immunofluorescence and Phallacidin Staining
Cells were cultured on FN coated 22 mm slides (BD
Biosciences) which were situated in 6 well tissue culture
plates, and inhibitors and blocking agents were added on
day 3, as above. Slides were removed on day 6 and cells
were fixed in 3.7% formaldehyde in PBS for 10 min. For
phalloidin staining, slides were blocked in 1% bovine
serum albumin (BSA) for 30 min and incubated in
BODIPY-Phallacidin (green) or rhodamine phalloidin (red)
(Molecular Probes) at room temperature for 20 min. For
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5% BSA for one h, incubated with primary antibodies
diluted in PBS 0.1% TRITON X-100, with overnight
incubation at 4°C (Santa Cruz Biotechnology). Coverslips
were washed and incubated with ALEXA FLOUR conju-
gated antibodies (Molecular Probes) and mounted on glass
slides using Prolong Gold with Dapi (Molecular Probes).
Cells were viewed and photographed using a ZEISS
Axiovert 200 M microscope fitted with an ApoTome
Imaging system. Phalloidin staining was quantitated on
400 x magnification. RhoA, GRAF and p190 Rho GAP
indirect immunofluorescence slides were photographed at
630 x. Phospho-FAK Y397 quantitation was performed on
an Olympus BX20 fluorescence microscope and an
Olympus MagnaFire digital photographic system at
1,000x magnification.
Immunoprecipitation, Rho GTP Assays and Western Blots
For Immunoprecipitation, cells were incubated at clonogenic
density on 10 cm fibronectin-coated plates, and cultured as
above, harvested and lysed on day 6 in 1X modified RIPA
buffer (Millipore) (approximately 2.5 million cells or 1 mg
total protein). Pre-cleared lysates were subjected to immuno-
precipitation using 10ug FAK antibody-conjugated agarose
(Millipore) overnight at 4°C. Beads were washed in modified
RIPA lysis buffer and collected by centrifugation at 10,000 X
g, at 4°C. The beads were boiled in 1X Lamelli buffer
(BIORAD) for 5 min and subjected toSDS PAGE for western
blot analysis.
For Rho GTP assays, equal numbers of cells were used
because the dormant cells exhibited a larger cytoplasm to
nucleus ratio and contained approximately 20% more
protein than the growing cells (approximately 2.5 million
cells, or 1 mg protein). Cells were harvested and lysed
using 1X Mg Lysis buffer (Millipore). Rho GTP was
immunoprecipitated using rhotekin RBD-agarose slurry
(Millipore), which exclusively binds RhoGTP, according
to the manufacturer’s instructions. Beads were washed,
resuspended in 1X Laemmli buffer (Biorad) and subjected
to SDS PAGE and immunoblotting for RhoA (Santa Cruz
Biotechnology). For western blots, samples were trans-
ferred to PVDF membranes, blocked in 2% BSA 1X TBS-
T, followed by addition of primary antibodies (SantaCruz
Biotechnology and Millipore) and detected via chemilumi-
nescence (Amersham).
Transfection and RhoA Constructs
RhoA DNA constructs, (kind gifts of Ian Whitehead), were
grown as described [31]. Briefly, cDNAs encoding human
wild-type RhoA, fused to an NH2-terminal hemagluttinin
(HA)-epitope tag were generated and cloned into pAX142.
An identical mutant panel was generated for each isoform:
RhoA-19N (dominant-inhibitory), RhoAWT (wild type), and
RhoA-63L (constitutively active) [32]. DNA was isolated
from bacterial cultures using Highspeed Plasmid MAXI Kit,
(Qiagen) according to the manufacturer’s instructions. RhoA
constructs were transfected using Fugene6 transfection
reagent (Roche) according to the manufacturer’si n s t r u c t i o n s
into MCF-7 cells cultured at clonogenic density on FN
coated coverslips. Rho constructs were co-transfected with
pmaxGFP DNA (AMAXA) at previously optimized concen-
trations for maximum transfection efficiency at ratios of 10:1
or 3.0 μg RhoA constructs/0.3 μg GFP vector DNA.
Medium was replenished at 12 h, and FGF-2 10 ng/ml was
added on day 2 after transfection. Cells were stained with
rhodamine phalloidin on day 4 following transfection, as
described above. Cells were counted as having cortical actin
rearrangement when >50% of the cell’s periphery was
subtended by cortical actin. GFP positive cells in dormant
clones (consisting of < 12 cells) or in growing clones (> 30
cells) were used for quantitation. Triplicate cover slips were
independently transfected in two separate experiments.
Means and standard deviations for data collected from green
fluorescent cells on the three slides were calculated in each
experiment and the significance of differences between
different vector transfections were determined using Stu-
dent’s t test.
Cell Fractionation
The Qiagen Qproteome Cell Compartment fractionation kit
( Q i a g e n )w a su s e dt oi s o l a te plasma membranes and
cytoplasmic fractions from cells in dormant or growing
clones according to the manufacturer’s protocol. Briefly,
equal numbers of cells from dormant (+FGF-2) or growing
(-FGF-2) clones cultured on FN-coated plates were sub-
jected to sequential centrifugation during which soluble
fractions containing plasma membrane and cytosolic frac-
tions were extracted. Fractions were subjected to SDS
PAGE and immunoblotted with anti-GRAF goat polyclonal
antibody (Santa Cruz Biotechnology) and anti-BAX anti-
body as a localization control.
Results
Integrin α5β1 Binding is Necessary for Cortical Actin
Redistribution in Dormant Cells
Using a three component system consisting of cells, FGF-2
10 ng/ml and fibronectin, we previously demonstrated that
estrogen sensitive human breast cancer cells become quies-
cent,re-expressintegrinslostwithmalignantde-differentiation
and acquire a spread appearance with increased cytoplasm to
RhoA inactivation in breast cancer dormancy 35n u c l e u sr a t i o s[ 3]. To determine if the appearance of the cells
in the dormant clones was due to cortically rearranged F-
actin, a characteristic of non-transformed mammary epithelial
cells [33], we stained them with phallacidin. Figures 1 aa n d
b demonstrate that 74.1+7.8% of these very large, quiescent
cells have parallel bundles of cortical actin as compared with
33.0+11.5% of cells in growing colonies. This difference is
significant at p<0.01 (Student’s t test). Analogously, MCF-
10A non-transformed, immortalized mammary epithelial
cells incubated on fibronectin also have a cortical actin
distribution. To test the hypothesis that the re-differentiated
state depends on outside-in signaling through re-expressed
integrin α5β1, we incubated the cells growing on fibronectin
with blocking antibodies to this integrin. Figure 2 a
demonstrates that cortical rearrangement of F-actin requires
binding of integrin α5β1 by fibronectin, while blocking
antibody to integrin α2β1, also upregulated in these dormant
cells [3], has no effect and acts as a negative control. The
increase in the percent cells with cortical actin from 28.6+
0.9% of growing cells to 67.9+6.6% of dormant cells
and the decrease back to 21.6+8.5% due to blocking of
integrin α5β1 binding are statistically significant (p<0.005,
p<0.001, respectively, Fig. 2b). Antibody to integrin α2β1
had no effect with 66.0+13.2% of the cells having cortical
actin (p>0.05). Other characteristics of these dormant cells,
including increased nuclear size (Fig. 2c) and increased
Fig. 1 Cortical actin stabilization in dormant breast cancer cells. a
MCF-7 cells incubated with or without FGF-2 10 ng/ml on
fibronectin-coated cover slips for 6 days at clonogenic density were
stained with BODIPY-Phallacidin (green actin staining) and DAPI
(blue nuclear staining) and photographed at 400 x magnification (see
Materials and Methods). A 20 μM size bar is included in all
fluorescence photographs in all figures. MCF-10A cells were
incubated on fibronectin-coated slides and stained in a similar manner
as controls and demonstrate morphological similarity with dormant
MCF-7 cells. Arrows indicate prominent places of cortical actin
redistribution around the perimeter of the cytoplasm. b The percen-
tages of cells with cortical actin distribution of >50% of the perimeter
were manually counted in approximately 100 cells and graphed.
Experiments were done in triplicate slides. Error bars are + standard
deviations. *p<0.01 (Student’s t test)
Fig. 2 Cortical actin stabilization in dormant breast cancer cells is
integrin α5β1-dependent. MCF-7 cells were incubated with or
without FGF-2 10 ng/ml on fibronectin-coated cover slips at
clonogenic density. Blocking antibodies to integrin α5β1 and integrin
α2β12μg/ml were added on day 3. Cells were stained with
rhodamine phalloidin (red actin staining) and DAPI (blue nuclear
staining) and photographed at 400 x magnification. A 20 μM size bar
is included in all photographs. a Blocking antibody to integrin α5β1,
the fibronectin receptor upregulated in dormant MCF-7 cells,
reversed the cortical redistribution of fibrillar actin, the increased
nuclear size and the increased cytoplasm to nucleus ratios in
dormant cells. Blocking antibody to integrin α2β1, the upregulated
collagen receptor, had no effect. b Quantitative representation of the
percentage of manually counted cells with cortical actin on triplicate
slides from a duplicate experiment. c Quantitative representation of the
maximal longitudinal axis of the nuclei and d Quantitative representa-
tion of the square of the ratio of the maximal cytoplasm long axis to that
of the maximal nuclear long axis. Error bars are + standard deviations.
*p<0.005, **p<0.001 (Student’s t test)
b
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reversed by blocking antibody to integrin α5β1. The mean
longitudinal nuclear axis increased from 15.4+2.0 μmi n
growing cells to 26.7+3.7 μm in dormant cells (p<0.001)
and was reversed to 19.8+4.0 with blocking antibody to
integrin α5β1( p<0.001). Blocking antibody to integrin
α2β1 did not have an affect. Similarly, the mean square of
the cytoplasm to nucleus ratios increased from 4.6+1.9 in
growing cells to 17.2+10.7 in dormant cells and was
reversed to 9.48+5.6 with blocking antibody to integrin
α5β1( p<0.001). Blocking antibody to integrin α2β1d i d
not have an affect on this characteristic either.
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for Cortical Actin Redistribution in Dormant Cells
We measured the activation of Rho A responsible for
modulating actin polymerization dynamics. Figure 3a
demonstrates that Rho A GTP levels were significantly
diminished in the dormant cells as compared to those in
growing cells. The effect depended on specific integrin
α5β1 binding by fibronectin, as blocking antibody to
integrin α5β1 restored RhoA activation while blocking
antibody to integrin α2β1 had only a partial effect. The
Rho A GTP-loaded state and its dependence on integrin
α5β1 activation is reflected in membrane localization of
Rho A in growing cells on fibronectin, re-internalization in
dormant cells and relocalization to the membrane by
blocking antibodies to integrin α5β1 in immunofluores-
cence assays (Fig. 3b).
To determine if the actin reorganization was dependent
on RhoA inactivation, we transfected cells on fibronectin-
coated cover slips with wild type, constitutively active and
dominant negative RhoA expression vectors and quantitat-
ed the percentage of transfected cells with cortical actin by
indirect immunofluorescence. Cells were transiently co-
transfected with a GFP vector and ten-fold excesses of the
various RhoA expression vectors. Actin localization in
green fluorescent cells was determined by rhodamine red
phalloidin staining. Figure 4a demonstrates prototypical
membrane localization of actin in GFP-only- and dominant
negative RhoA 19N-transfected dormant cells and signifi-
cantly diminished peripheral actin localization in wild type-
or constitutively active Rho 63L-transfected dormant cells.
In the latter transfectants, the appearance of stress fibers
became evident. The data, graphed in Fig. 4b, confirms
once again the increase in the percentage of cells with
cortically rearranged actin around more than 50% of the
periphery from 9+0.7% of the growing cells to 80+2% of
the dormant cells (p<0.01). No significant differences were
noted between mock transfected and GFP only-transfected
Fig. 3 Downregulation of RhoA GTP-loading in dormant MCF-7
breast cancer cells is integrin α5β1-dependent. a Cells were incubated
on 10–12 fibronectin-coated 10 cm plates per condition and cultured as
described. On day 6, equal cell numbers were lysed, incubated with
Rhotekin-conjugated agarose, precipitated and analyzed by western
blot with anti-RhoA antibody. Total lysates were used for RhoA
western blot controls and a nonspecific band on the Coomasie-stained
membrane was used as a loading control to confirm the increased
protein content of dormant cells. RhoA GTP and total Rho bands were
quantitated with a densitometer and ratios were normalized to that of
growing cells. The experiment was done three times. b The RhoA
GTP-loading data was corroborated by indirect immunofluorescence-
staining of cells on fibronectin-coated cover slips with anti-RhoA
antibody (red) and photography at 630 x magnification. Growing cells
exhibited membrane localization of RhoA (arrows) which disappeared
in dormant cells. Blocking antibody to integrin α5β12μg/ml induced
re-localization of RhoA to the membrane, while blocking antibody to
integrin α2β12μg/ml had only a minimal effect. Nuclear DAPI
staining is shown in blue
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negative RhoA 19N did not decrease the percentage of cells
with cortical actin. However, transfection with constitutive-
ly active 63L and wild type RhoA decreased the percentage
of cells with cortical actin to 24+2( p<0.001) and 10+4%,
(p<0.02), respectively. These data demonstrate that inacti-
vation of RhoA is necessary to permit the acquisition of the
dormant phenotype. To determine if inactivation of RhoA
Fig. 4 Downregulation of RhoA GTP-loading is necessary but not
sufficient for cortical actin rearrangement in dormant cells. Cells on
fibronectin-coated cover slips in medium containing FGF-2 10 ng/ml
(A. and B.) or lacking FGF-2 (C. and D.) were transiently transfected
with 10:1 ratios of the three RhoA vectors and the GFP vector or with
the GFP vector alone and stained with rhodamine phalloidin (red) and
DAPI (blue nuclear staining). Cortical actin was identified and
quantitated in the GFP-transfected green cells only. a Cortical
distribution of F-actin was observed in GFP only- and RhoA 19N
(dominant negative)-transfected dormant cells (arrows), but was
markedly diminished in dormant cells transfected with RhoA63L
(constitutively active) or RhoA wild type (RhoAWT). These latter two
transfectants also induced the appearance of stress fibers. Cells were
photographed at 400 x magnification. b Quantitative assessment of the
percentage of cells with >50% cortical distribution demonstrates a
statistically significant increase in cortical actin in dormant cells
compared with growing cells (*p<0.01), between GFP- and
RhoA63L-transfected dormant cells (**p<0.001) and between GFP-
and RhoAWT-transfected dormant cells (***p<0.02) (Student’s t test).
Error bars are + standard deviations. All other differences were not
statistically significant. c Transfection of growing cells with dominant
negative RhoA19N did not induce either the dormant phenotype or
actin rearrangement. Transfection with either constitutively active
RhoA63L or wild type RhoA also did not affect cortical actin (not
shown). D. Statistical comparison of cell distributions with cortical
actin was not affected in growing cells by dominant negative
RhoA19N, nor by the other vectors (not shown)
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by a spread cellular appearance and cortical actin redistri-
bution, growing cells were transfected with dominant
negative RhoA 19N vector. Figure 4c demonstrates that
the cells did not acquire the characteristic appearance and
did not develop cortically rearranged actin. Figure 4d
demonstrates that there was no statistically significant
increase in the percentage of cells with cortical actin
between GFP only-transfected and RhoA 19N-transfected
growing cells, nor did the cells acquire the typically large,
spread out appearance of the dormant cells. Transfection
with wild type and dominant negative vectors had no effect
either, as expected (data not shown). These data demon-
strate that the inhibition of RhoA activation is not sufficient
to induce the dormant phenotype.
Activation of Focal Adhesion kinase in Dormant Cells
is Associated with Membrane Localization of the GTP
Activating Protein GRAF
We investigated whether focal adhesion kinase (FAK) was
affected in dormant cells as part of the re-differentiation
process. Integrin-mediated cell adhesion activates FAK and
results in focal adhesion complex formation, initiation of
stress fiber formation and motility [34]. The cellular levels
Fig. 5 Peripheral phospho-Y397 FAK localization in dormant cells is
integrin α5β1-dependent. a MCF-7 cells were incubated on fibronec-
tin-coated cover slips with medium containing FGF-2 10 ng/ml.
Blocking antibodies to integrin α5β1 and integrin α2β12μg/ml and
blocking peptides to fibronectin (P1), to collagen (P3), and a non-
binding control (P2) 100 nM were added on day 3 as described in
Materials and Methods. Cells were stained with antibodies to
phospho-Y397 FAK on day 6 and photographed at 1,000 x
magnification. Localization of phospho-Y397 FAK with dormancy is
reversed by blocking fibronectin binding with blocking antibody to
integrin α5β1 or blocking peptide P1 to fibronectin. b Graphic
depiction of induction of peripheral phospho-Y397 FAK in dormant
cells (*p<0.005), and reversal of localization by blocking antibody to
integrin α5β1 (**p<0.001) and blocking peptide to fibronectin P1
(***p<0.01) (Student’s t test). Error bars are + standard deviations.
All other differences were not statistically significant. Data is from one
of two duplicate experiments with triplicate slides with approximately
100 cells counted per slide
Fig. 6 Integrin α5β1-dependent peripherally localized phospho-Y397
FAK in dormant cells is associated with membrane localization of the
RhoA GAP GRAF. a Cells incubated on fibronectin-coated tissue
culture plates with and without FGF-2 10 ng/ml with control or
blocking antibodies to integrin α5β1 and integrin α2β12μg/ml
added on day 3 were harvested on day 6. Lysates from equal cell
numbers were immunoprecipitated with antibody to FAK and stained
on western blot with anti-phospho-Y397 FAK antibody, total FAK
antibody and GRAF antibody. Bands were quantitated using a
densitometer and ratios of phospho-FAK to FAK and GRAF to
phospho-FAK were normalized to the bands from dormant cells in the
immunoprecipitates. Ratios of phospho-FAK to total FAK and total
FAK to control bands were also normalized to dormant cells. b GRAF
membrane localization in dormant cells and the corresponding RhoA
departure form its membrane localization was demonstrated on
immunofluorescence-stained cells on fibronectin-coated cover slips
(red) and photography at 630 x magnification. Growing cells exhibited
membrane localization of RhoA (arrows) which disappeared in
dormant cells, while GRAF membrane localization appeared in
dormant cells (arrows). Immunostaining with antibody to p190 Rho
GAP was used as a negative control, demonstrating no evident
staining in either growing or dormant cells. Nuclear DAPI staining is
shown in blue. c Membrane fractionation of growing and dormant
cells with and without added blocking antibodies to integrin α5β1 and
integrin α2β12μg/ml and western blotting of isolates with antibody
to GRAF and BAX, used as a cytoplasm-localizing control. Bands
were quantitated using a densitometer and ratios of membrane- to
cytoplasm-localizing GRAF and BAX were calculated
b
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progression [35–39]. In this context however, we found that
instead of inactivation with dormancy, FAK became mem-
brane localized and activated in the dormant cells. The
percentage of cells staining for peripheral, activated Y397
phospho-FAK increased from 16.5+8.6% of growing cells
to 83.1+12.6% of dormant cells (p<0.005) (Fig. 5). This
activation depended on binding of integrin α5β1, as integrin
α5β1 blocking antibody or fibronectin blocking peptide P1
incubated with dormant cells decreased the percentage of
cells with peripherally staining activated FAK to 15.9+2.9%
(p<0.001) and 32.2+9.5% (p<0.01), respectively. Control
blocking antibody to integrin α2β1, non-binding control
peptide P2 or collagen blocking peptide P3 had no effect,
with peripheral FAK activation remaining at 70.6+4.5%,
83.6+4.9% and 65.7+4.7%, respectively, in dormant cells.
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lysates prepared from dormant and growing cells and
immunostained western blots with antibodies to phospho-
Y397 FAK and total FAK. Figure 6a demonstrates that total
FAK levels decreased in dormant cells as demonstrated by
IP/western blots, while phospho-Y397 FAK levels in the
cells slightly increased. The increase in phospho-Y397 was
dependent on integrin α5β1, as blocking antibody de-
creased the rate of this phosphorylation in the IP/westerns,
while blocking antibody to integrin α2β1 had no effect.
The overall increase in phospho-Y397 FAK was small
when whole cellular lysates were assayed by IP/western
blot in all of the experiments, while the decreases with
integrin α5β1 blocking antibody were consistent. However,
the physiologically significant increase in membrane
localization of activated FAK was markedly pronounced
and significant, as demonstrated by the immunofluores-
cence staining for phospho-FAK.
To determine a possible mechanism for the inactivation
of RhoA in dormant cells, we analyzed the FAK immuno-
precipitates for GTPase Regulator Associated with the
Focal Adhesion Kinase pp125(FAK) (GRAF), a protein
with demonstrated RhoA GAP activity shown to co-
localize with activated FAK in focal complexes. Figure 6a
suggests that GRAF becomes associated with FAK in
dormant cells, an effect exclusively dependent on integrin
α5β1. To confirm this result, we analyzed the cells by
immunfluorescence. Figure 6b demonstrates that GRAF
became membrane localized in the dormant cells in a
reciprocal relationship to the loss of RhoA membrane
localization. As a control, Fig 6b demonstrates that the
RhoA GAP p190 was not affected in dormant cells. To
further confirm the activation by membrane localization of
GRAF in dormancy, we carried out membrane fractionation
experiments. Figure 6c demonstrates that GRAF was
primarily cytoplasm localized in growing cells with a
membrane to cytoplasm (m/c) ratio of 0.25. In dormant
cells, GRAF membrane localization increased to an m/c
ratio of 0.61. This effect once again was dependent on
integrin α5β1, as blocking antibody to this integrin
decreased the ratio to 0.15. With blocking antibody to
integrin α2β1 used as a control, the GRAF m/c ratio was
0.80. These data support the hypothesis that the RhoA GAP
GRAF becomes activated and membrane localized in
dormant cells causing an inactivation of RhoA and that
this effect depends on binding of integrin α5β1.
Activation of PI3K is Independent of Integrins α5β1
Binding in Dormant Cells
We have previously demonstrated that the PI3K pathway is
activated in these dormant cells [3]. This activation is
sustained for the 5 days assayed and its inhibition blocked
survival of the dormant clones. We investigated whether the
activation of the PI3K survival pathway was dependent on
binding of integrins α5β1. Figure 7 is a western blot that
demonstrates that inhibiting integrin α5β1 binding with
blocking antibody or blocking peptide P1 had no effect on
Akt phosphorylation. An inhibitor of PI3K, LY294002, was
used as a positive control. These data suggest that PI3K
activation by FGF-2 is mediated directly by FGF-2-mediated
signaling, independent of signaling by integrin α5β1.
PI3K Activation is Necessary for Cortical Actin
Redistribution in Dormant Cells
To determine if dual signaling by FGF-2 through PI3K as
well as ligation of the upregulated integrin α5β1 is required
for the cortical actin rearrangement in the dormant cells, we
incubated the cells with the PI3K inhibitor LY294002.
Figure 8a demonstrates that dormant cells incubated with
LY294002 lost their spread appearance and their cortical
actin rearrangement and developed stress fibers. Figure 8b
shows that the percentage of cells with cortical actin
increased from 33.1+11.5% in growing cells to 74.2+7.7
in the dormant cells (p<0.01), an effect reversed by the
PI3K inhibitor to 30.88+15.5% (p<0.01). These data
suggest that dual signaling by FGF-2 directly through
PI3K and through integrin α5β1 is necessary for cortical
rearrangement in dormant cells.
Membrane Localization of GRAF and Inactivation of RhoA
Require PI3K Activity
Since guanine exchange factors and GTP activating proteins
have both been linked to PI3K activity, we investigated
whether the inactivation of RhoA in dormant cells was
dependent on activation of PI3K. Figure 9ad e m o n s t r a t e st h a t
both the loss of membrane localization of RhoA and the
reciprocal membrane re-localization of GRAF in dormant
clones are reversed by inhibition of PI3K with LY294002.
Fig. 7 Akt activation by FGF-2 in dormant cells is independent of
integrin α5β1 ligation. Western blots of lysates from cells incubated
on fibronectin with and without FGF-2 10 ng/ml or blocking
antibodies to integrin α5β1 or integrin α2β12μg/ml, blocking
peptide P1 to fibronectin 100 nm, or PI3K inhibitor LY294002 25 μM
on day 3, as described in Materials and Methods, were stained with
antibody to phospho-Akt or total Akt
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for GRAF that demonstrated that the change in the GRAF m/
c ratio from 0.46 to 1.21 from growing to dormant cells was
reversed to 0.23 by incubation of cells with the PI3K
inhibitor (Fig. 9b). These experiments demonstrate that the
activation of GRAF, inactivation of RhoA and the cortical re-
distribution of fibrillar actin in dormant cells require PI3K
activation.
Figure 10 depicts a summary of the data presented
demonstrating the factors that modulate the elements of
dormancy assayed in this model. It indicates that FGF-2-
initiated signaling induces an upregulation of integrin α5β1
over a period of several days. Dual signaling by FGF-2
through PI3K and independent signaling through integrin
α5β1 induce activation of FAK and membrane localization
and activation of the RhoA GAP GRAF. This results in
inactivation of RhoA and a permissive steady state for
cortical rearrangement of F-actin. Follow up investigations
into the transition to this steady state are ongoing.
Discussion
We have previously demonstrated that estrogen sensitive
breast cancer cells, analogous to ones likely to remain
dormant as microscopic metastases in the bone marrow
microenvironment of patients, can enter a state of relative
dormancy in an in vitro model [3]. The model encompasses
some key components of the bone marrow niche, which
include FGF-2 and fibronectin. Estrogen sensitive cells are
induced by FGF-2 to go into G1 arrest through induction of
cdk inhibitors [14], to re-express integrins lost with
malignant progression [3] and to develop a distinct
phenotype consisting of a large, spread out appearance,
large cytoplasm to nucleus ratios [3] and to acquire
resistance to chemotherapy with taxanes [26].
Here, we demonstrate that the spread appearance
corresponds to cortically rearranged fibrillar actin and
omnidirectionally activated FAK at the cell periphery.
Circumferential actin bundle formation is another element
of re-differentiation in these dormant cells. Cortical actin is
observed exclusively in nontransformed mammary epithe-
lial cells, disappears and is replaced by stress fibers during
malignant transformation [33]. These effects are similar to
ones we have previously demonstrated to occur with re-
differentiation of a highly malignant breast cancer cell line,
MDA-MB-231, upon enforced expression of FGF-2 [27], a
growth factor whose expression stops during the process of
mammary epithelial cell progression to malignancy [40].
The activation of FAK, however, appears to be
counterintuitive to the re-differentiation process when first
encountered. FAK activation is associated with integrin-
mediated adhesion and motility and is the mainstay of
focal adhesion complexes initiating stress fibers. FAK
Fig. 8 Cortical actin stabiliza-
tion in dormant breast cancer
cells is PI3K-dependent. a
MCF-7 cells incubated with or
without FGF-2 10 ng/ml on
fibronectin-coated cover slips at
clonogenic density, with and
without addition of LY294002
25 μM on day 3 were stained on
day 6 with BODIPY-Phallacidin
(green actin staining) and DAPI
(blue nuclear staining) and pho-
tographed at 400 x magnifica-
tion. The figure demonstrates
cortical actin distribution that
appears in dormancy and is
reversed by PI3K inhibition.
The appearance of stress fibers
and loss of the characteristic cell
spreading is evident in dormant
cells inhibited by LY294002. b
Quantitative representation of
manually counted cells with
cortical actin on triplicate slides
from a duplicate experiment
demonstrating an increase in
cortical actin with dormancy and
reversal with PI3K inhibition.
Error bars are + standard devia-
tions. *p<0.01 (Student’s t test)
RhoA inactivation in breast cancer dormancy 43levels are elevated and its activation plays a role in breast
cancer progression [35–39]. However, our data showing
that the activated FAK is complexed with GRAF in
dormant breast cancer cells supports a role in a more
differentiated state. GRAF is a protein with RhoA and
dcdc42 GAP activity discovered in leukemic cells [41].
GRAF binds to the C-terminal domain of FAK in an SH3
domain-dependent manner [42] and blocks Rho-mediated
stress fiber formation [43]. This can be regarded as
contributing to partial cancer cell re-differentiation, since
RhoA is the primary cause of stress fiber formation and
increased motility of cancer cells, and trends to higher
expression with tumor grade and nodal metastasis in
breast cancer [29]. This report is the first account for a
putative role for GRAF in the inactivation of RhoA in
dormant breast cancer cells in this in vitro model.
The inactivation of RhoA appears to be at steady state
and Rhotekin pulldown assays for RhoA GTP did not
demonstrate downregulation at earlier times (data not
shown). It is most likely that actin polymerization took
place before the steady state of dormancy was achieved,
and F-actin was stabilized in the cortical distribution after
Fig. 9 Membrane localization of GRAF in dormant cells is PI3K-
dependent. a GRAF membrane localization in dormant cells and the
corresponding RhoA departure form its membrane localization was
demonstrated on immunofluorescence-stained cells on fibronectin-
coated cover slips (red) and photography at 630 x magnification.
Addition of LY294002 25 μM on day 3 to the incubation medium
resulted in abrogation of the membrane localization of GRAF and a
corresponding membrane re-localization of RhoA (arrows). Growing
cells exhibited membrane localization of RhoA (arrows) which
disappeared in dormant cells, while GRAF membrane localization
appeared in dormant cells (arrows). Nuclear DAPI staining is shown in
blue. b Membrane fractionation of growing and dormant cells with and
without added LY294002 25 μM and western blotting of isolates with
antibody to GRAF and BAX, used as a cytoplasm-localizing control,
demonstrates that the membrane localization of GRAF in dormant
cells is reversed by blocking of PI3K signaling. Bands were
quantitated using a densitometer and ratios of membrane- to
cytoplasm-localizing GRAF and BAX were calculated
44 J. Barrios, R. Wiederinactivation of RhoA. We assayed for activation of both
Rac and cdc42 to determine the effects of dormancy on
other members of the small GTPase family. The GTP
loading of cdc42 was diminished, but Rac GTP loading was
unaffected (data not shown). The effect is likely due to
family member specificity of the GRAF family [42, 44, 45]
due to a favorable interaction of the GRAF 231-residue BH
domain, which harbors its GAP activity [46] with Glu-95 of
Cdc42 and Glu-97 of RhoA, and is absent in the
corresponding Ala-95 of Rac1 [44]. Rac and RhoA have a
reciprocal relationship, and Rac activity remains unchecked
with the inactivation of RhoA [47]. This is one likely
explanation for the distinct appearance of lamellopodia on
dormant cells (Figs. 1a, 3b, 4a, 5a, 6b, 8a, 9a). However,
without the ability to form stress fibers, the characteristic
motility due to Rac activation does not occur [48].
The role of PI3K in GRAF activation is also novel. We
demonstrated that the survival of these dormant cells
depends, in part, on activation of the PI3K pathway. The
data presented here demonstrate that parallel signaling
induced by exogenous FGF-2 through PI3K and by integrin
α5β1 is necessary for activation of this GAP. The levels of
GRAF were not affected in dormant cells as demonstrated
by western blot (data not shown). However, its membrane
localization depended on both exogenous FGF-2 through
PI3K and binding of integrin α5β1. The mechanism is not
understood and will be studied in follow up investigations.
However, an association with FAK has been demonstrated.
Whether this association is direct or through elements of the
well recognized large complex is yet to be determined and
will be investigated.
PIK3CA, the gene coding for the catalytic subunit of
P I 3 K ,i sm u t a t e di n1 8 –40% of breast cancers [49]. The
mutations are in “hotspots” in exons 9, corresponding to the
helical domain and exon 20, corresponding to the kinase
domain in 85–100% of cases [50, 51]. While the importance
of the PI3K pathway in mammary tumorigenesis has been
extensively investigated, opposing conclusions regarding
mutations in the PIK3CA gene in primary breast tumors
have been reached by different groups [50, 52]. A potential
explanation for the conflicting reports came to light more
recently when a more focused analysis reported that
mutations in exon 9 are associated with a significantly worse
prognosis for disease-free and overall survival while muta-
tions in exon 20 are associated with prolonged survival [51].
Also, while a mutation in Akt 1 has finally been identified in
a number of malignancies, including breast cancer [53], the
role of Akt activation in initiating malignant transformation
is yet to be clarified [54]. With respect to breast cancer
dormancy, the significance of frequent mutations in the PI3K
pathway is not at all understood. It is possible that activating
mutations may render cells resistant to therapy and permit
survival of metastatic cells in the bone marrow niche. We
have previously shown that the activated PI3K pathway is
necessary for survival of this dormancy model [3]b u t
induction of the dormant, non-proliferative state depends on
FGF-2-initiated signals that activate a variety of pathways in
addition to PI3K.
In conclusion, we have shown that dormancy of estrogen
sensitive breast cancer cells in a three component in vitro
model encompasses a partial re-differentiation of breast
cancer cells in close contact with elements of the micro-
environement, which consist of inhibition of proliferation,
re-expression of integrins lost with malignant transforma-
tion, cell spreading with omnidirectional FAK activation,
activation of the RhoA GAP GRAF through exogenous
FGF-2-mediated activation of PI3K and through integrin
α5β1 ligation, with a resultant inactivation of RhoA and
cortical actin rearrangement. Follow-up investigations will
determine the mechanisms of achieving this steady state or
dormancy and mechanisms for overcoming drug resistance
in the dormant cells. Additional components will be added
to the model, including a third dimension to validate the
biological implications of our data prior to in vivo
confirmation. In vivo effects of modulating RhoA activa-
tion in a murine metastasis model will confirm the
functional role of RhoA inactivation in maintaining
dormancy in micrometastases.
This model is one of several that have begun to
generate data and hypotheses regarding this little under-
stood but enormously significant biologic phenomenon.
Our model fits with the concept of reversible growth/
proliferation arrest or quiescence governed by a genetic
program which ensures the suppression of terminal
differentiation [55]. The panel of genes comprising this
state is activated regardless of the signal that initiates
Fig. 10 Schema of dual FGFR and integrin α5β1 parallel steady state
signaling in the dormancy model. The schema indicates FGF-2-
initiated upregulation of integrin α5β1 which reaches steady state
after several days. Dual signaling through FGFR through PI3K and
independently through integrin α5β1 induces activation of FAK and
membrane localization and activation of the RhoA GAP GRAF. This
results in inactivation of RhoA and a permissive steady state for
cortical rearrangement of F-actin
RhoA inactivation in breast cancer dormancy 45growth arrest. We have previously demonstrated that FGF-
2 initiates reversible growth arrest in MCF-7 and T-47D
cells [14] and that this effect is mediated through TGFβ
[56]. TGFβ and the BMP family are inhibitory to breast
cancer cells that have not undergone epithelial mesenchy-
mal transition [57] and can suppress micrometastases
when administered in vivo [58].
A well-developed model of dormancy demonstrates a
role for the urokinase receptor (u-PAR) activation in the
exit from dormancy [59]. The model describes the
upregulation of integrin α5β1, and the ability of the latter
to propagate signals from fibronectin through the EGF-
receptor and ERK to cause single quiescent cells to enter
the cell cycle [59]. Similarly, a recent model of breast
cancer dormancy demonstrated that the transition from
quiescence to proliferation of breast cancer cells was
dependent on fibronectin production and signaling through
integrin β1, leading to cytoskeletal reorganization with
F-actin stress fiber formation [60]. These models are
completely congruent with our hypothesis, despite first
impressions. We have previously demonstrated that fibro-
nectin increases the number of dormant MCF-7 and T-47D
clones incubated with FGF-2, but nevertheless, the cells
remain dormant [3]. The likely explanation is that activation
of proliferative signaling by ligation of integrin α5β1b y
fibronectin and by FGF-2 mediated activation of the ERK
pathway and upregulation of cyclin D [14] are trumped by
FGF-2-induced parallel cell cycle inhibition and partial
rediferrentiation. FGF-2-initiated signaling results in upregu-
lation of p21
WAF1/Cip1 [14] and p27
KIP1 [56]a n dr e -
expression of integrins lost with de-differentiation [3], which
collectively contribute to the dormant phenotype observed.
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